The global antisense and RNAi therapeutics market is anticipated to reach USD 4.58 billion by 2022, according to a new report by Grand View Research, Inc. Technological development in the drug delivery technology based on liposome and nano biotechnology is expected to provide the market with a high potential to grow due to enhancement in the adoption of gene silencing therapeutic product models.
The RNAi therapeutic industry has an extensive product portfolio in the pipeline and expected commercialization of these products is expected to fuel growth in demand over the next seven years.
A number of major market participants have strong intellectual property portfolios for various RNAi related methods and usages, based on which there are a considerable number of therapeutics in different phases of discovery, and development clinical trials for mainly cancer and cardiology associated disorders.
Furthermore, strategic collaborations intended by the market participants for availing licensed developmental use for proprietary RNAi technology platforms is another major source for generation of revenue in the market from amongst these entities.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the report suggest:
RNA interference accounted for the largest share of market revenue in 2014 owing to the ability of RNA-blocking oligo nucleotides in the manipulation of gene function that makes them best suited for the treatment of genetic disorders and other chronic diseases.
Moreover, positive results obtained from the clinical trials for the treatment of Duchenne muscular dystrophy prove that this technology is close to achieving its clinical potential. RNAi can also be employed for reduction of the levels of toxic gain-of-function proteins, block viral replication, and trigger cytotoxicity within tumors.
Applications of RNAi therapeutics in oncology accounted for a sizeable 19% of the revenue generated in 2014. Higher incidence of cancer extenuates the need for extensive R&D investment for cancer therapeutics.
Due to the growing need for unconventional methods to check cancer associated mortality, market participants are involved in the development &introduction of novel biomolecules that can be used with a higher efficiency in targeting different cell surface receptors and tumor marker genes in attempts to prevent post-translational tumor modifications.
Developmental revenue flowing into R&D for RNAi delivery through pulmonary routes of administration dominated the segment in 2014 owing to higher efficacy exhibited by the clinical trials based on the respiration based routes of drug transfer for a number of lungs associated disorders.
A number of delivery technologies are under focused investigation to evolve the current methods further and enhance efficiency to other specific organ targets as well. The presence of several drugs in the phases of clinical trials for administration via systemic and pulmonary route is a supportive factor expected to drive growth in this sector.
North America dominated the industry in 2014, with revenue estimated at over USD 400 million. Presence of a number of major market entities headquartered in this region coupled with their collaborations with academic institutions and smaller clinical stage biopharmaceutical companies for research is expected to impact growth positively over the forecast period.
Key players operating in this market include Tekmira Pharmaceuticals/Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense Therapeutics, Silence Therapeutics, Isis Pharmaceuticals, Sirnaomics, Santaris / Roche.
These entities are involved in a significant number of collaborations for RNAi R&D with clinical research organizations, therapeutic product discovery and development laboratories, and academic institutes in order to reduce the in-house expenses involved in the discovery, development, and preclinical development.
Moreover, focus on product versus platform technologies and virtual drug development models that enable companies to reduce the research cost coupled with target specificity and selectivity associated with the use of RNAi therapeutics are factors expected to serve the market with a number of lucrative avenues to grow through to 2022.
Grand View Research has segmented Antisense and RNAi therapeutics market on the basis of technology, application, route of administration and region:
Global RNAi and Antisense Therapeutics Market, by Technology (Revenue, USD Million, 2012 - 2022)
Global RNAi and Antisense Therapeutics Market, by Application (Revenue, USD Million, 2012 - 2022)
Global RNAi and Antisense Therapeutics Market, by Route of Administration (Revenue, USD Million, 2012 - 2022)
Other Delivery Methods
Global RNAi and Antisense Therapeutics Market, by Region (Revenue, USD Million, 2012 - 2022)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.